Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
This study has finished and is no longer accepting participants.
Multiple locations, including HefeiResearchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixA Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Read the official source — NCT00650611A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including San DiegoA Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Read the official source — NCT00550238A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
This study has finished and is no longer accepting participants.
Multiple locations, including GilbertThis study evaluated the safety and effectiveness of SP-624 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveThis study evaluated the safety of RO5545965 for people with schizophrenia.
This study has finished and is no longer accepting participants.
In GlendaleA Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects
This study has finished and is no longer accepting participants.
In New HavenA Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease
This study has finished and is no longer accepting participants.
In AuroraA Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease
This study has finished and is no longer accepting participants.
In Aurora
A Sham-controlled Study of Transcranial Direct Current Stimulation (tDCS) as a Treatment for Depression
This study has finished and is no longer accepting participants.
In RandwickResearchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including RijekaA Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
Read the official source — NCT00216632Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)
This study has finished and is no longer accepting participants.
Location not clearly listedWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.